Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04084860 · ClinicalTrials.gov registry record · Phase 2
The Role of Brief Potent Glutamatergic Modulation in Addressing Problem Drinking
A Phase 2 study, sponsored by New York State Psychiatric Institute.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
NCT04084860 is a Phase 2 study that is actively recruiting participants, run by New York State Psychiatric Institute. The registered enrollment target is 120 participants.
The verdict
NCT04084860, a Phase 2 study, is actively recruiting participants, sponsored by New York State Psychiatric Institute.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
Study Summary
The proposed project tests the efficacy of glutamate modulators in non-depressed individuals with alcohol use disorder (AUD); the primary hypothesis is that the glutamate modulator being tested reduces heavy drinking days compared to the active control. It also aims to investigate, using a 2 by 2 factorial (2x2) design, the hypothesis that the effects of the glutamate modulator are enhanced when combined with behavioral treatment.
Interventions
- DRUG CI-581a
- DRUG CI-581b
- BEHAVIORAL MET
- BEHAVIORAL MBRP
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2019-11-08 |
| Est. Completion | 2024-08-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04084860
The ClinicalTrials.gov registry entry for NCT04084860 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which CI-581a is the first listed.
NCT04084860 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04084860 about?
NCT04084860 is a clinical study titled "The Role of Brief Potent Glutamatergic Modulation in Addressing Problem Drinking". The proposed project tests the efficacy of glutamate modulators in non-depressed individuals with alcohol use disorder (AUD); the primary hypothesis is that the glutamate modulator being tested reduces heavy drinking days compared to the active control. It also aims to investigate, using a 2 by 2 fa...
What is the current status of trial NCT04084860?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2019-11-08. Estimated completion is 2024-08-31.
What interventions are being tested in trial NCT04084860?
The interventions under investigation include: CI-581a (DRUG), CI-581b (DRUG), MET (BEHAVIORAL), MBRP (BEHAVIORAL).
Who is sponsoring clinical trial NCT04084860?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.